ProfileGDS5678 / 1442791_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 71% 71% 68% 71% 73% 73% 71% 70% 69% 70% 69% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8198674
GSM967853U87-EV human glioblastoma xenograft - Control 24.4319971
GSM967854U87-EV human glioblastoma xenograft - Control 34.4634771
GSM967855U87-EV human glioblastoma xenograft - Control 44.1845568
GSM967856U87-EV human glioblastoma xenograft - Control 54.4084171
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.578673
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6344473
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4295771
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3582270
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3157369
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3442970
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2774169
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4504171
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4213671